-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Golcadomide in Diffuse Large B-Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Golcadomide in Diffuse Large B-Cell Lymphoma Drug Details: CC-99282 is under development for the treatment...
-
Product Insights
Ischemia Reperfusion Injury – Drugs In Development, 2023
Global Markets Direct’s, ‘Ischemia Reperfusion Injury - Drugs In Development, 2023’, provides an overview of the Ischemia Reperfusion Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Kidney Transplant Rejection – Drugs In Development, 2023
Global Markets Direct’s, ‘Kidney Transplant Rejection - Drugs In Development, 2023’, provides an overview of the Kidney Transplant Rejection pipeline landscape. The report provides comprehensive information on the therapeutics under development for Kidney Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Hemoglobinuria – Drugs In Development, 2023
Global Markets Direct’s, ‘Hemoglobinuria - Drugs In Development, 2023’, provides an overview of the Hemoglobinuria pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hemoglobinuria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Paroxysmal Nocturnal Hemoglobinuria – Drugs In Development, 2023
Global Markets Direct’s, ‘Paroxysmal Nocturnal Hemoglobinuria - Drugs In Development, 2023’, provides an overview of the Paroxysmal Nocturnal Hemoglobinuria pipeline landscape. The report provides comprehensive information on the therapeutics under development for Paroxysmal Nocturnal Hemoglobinuria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Periodontitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Periodontitis - Drugs In Development, 2023’, provides an overview of the Periodontitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Periodontitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Glomerulonephritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Glomerulonephritis - Drugs In Development, 2023’, provides an overview of the Glomerulonephritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Glomerulonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Periodontal Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Periodontal Disease - Drugs In Development, 2023’, provides an overview of the Periodontal Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Periodontal Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TAK-186 in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TAK-186 in Non-Small Cell Lung Cancer Drug Details: TAK-186 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AMY-101 in Kidney Transplant Rejection
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AMY-101 in Kidney Transplant Rejection report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AMY-101 in Kidney Transplant Rejection Drug Details: AMY-101 (Cp-40) is under...